{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2015"],"condition":["Cancer-Bowel-Back passage (rectum) or large bowel (colon)","Cancer-Liver","Resection of colorectal liver metastases","Surgery-Surgical techniques"],"disease":["Surgery-surgical Techniques","Cancer-bowel-back Passage (rectum) Or Large Bowel (colon)","Resection Of Colorectal Liver Metastases","Cancer-liver"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2462248"],"location":["New Zealand","Australia"],"study_start_month":["9"],"repository":["ECRIN MDR"],"study_status":["Terminated"],"additional_accession":[]},"is_claimable":false,"name":"In colorectal metastases patients who require liver resection, does a surgeon having knowledge of liver fat measurements influence surgical planning decisions that result in improved patient outcomes.","description":"Intervention arm – the surgeon will have knowledge of a quantitative measure of liver fat from MRI (HepaFat-Scan)\nPrimary Outcome 1: all cause mortality as assessed by data linkage to medical records[Timepoint: within 3 months post surgery];Primary Outcome 2: postoperative complications as assessed by data linkage to medical records (e.g. ascites, urine infection, bilioma, renal failure)[Timepoint: at baseline and 6 months post surgery];Primary Outcome 3: deviations from standard surgical treatment as assessed by qualitative questionnaire designed specifically for this study[Timepoint: baseline]\nStudy Design: Purpose: Treatment; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Safety/efficacy","dates":{"creation":"2015-09-15"},"accession":"2462248","cross_references":{"Australian New Zealand Clinical Trials Registry":["ACTRN12615000567527"]}}